Samsung Biologics, AstraZeneca to dissolve biosimilar JV, scrap Rituxan copy program: report

Back in 2014, Samsung Biologics and AstraZeneca set up a joint venture to develop a biosimilar to Roche’s blockbuster cancer drug Rituxan. Fast-forward to 2020, and the pair has admitted defeat.

Archigen Biotech, a 50-50 JV between Samsung and AstraZeneca, will stop development of a Rituxan copycat dubbed SAIT101, Korea Biomedical Review reported, citing Samsung Biologics’ third-quarter report.